FDA 向印度 Glenmark 果阿 Colvale 工厂签发 483,列出清洁时间、报警管理与 Empower 数据预览等六项观察
FDA483:GMP报警策略,empower预览
FDA 就 2026 年 6 月 22 日至 30 日对印度 Glenmark 制药果阿 Colvale 工厂的检查签发 483,列出六项观察。观察涉及 A 类与 B 类清洁记录时间不足以完成规定步骤、未建立经验证的最低清洁时间与消毒剂接触时间、非关键报警缺少频率或严重性调查触发点,以及 Empower 用户权限允许分析员在更改处理方法时查看峰面积而不保存色谱图。
同一件事,精选收录的是《FDA 公布 Glenmark 印度果阿制剂厂 483 检查报告,共列 6 项观察》
表头信息 / Header Information
DEPARTMENT OF HEALTH AND HUMAN SERVICES | 美国卫生与公众服务部 |
DISTRICT ADDRESS AND PHONE NUMBER | 地区办公室地址与电话 |
DATE(S) OF INSPECTION | 检查日期 |
FEI NUMBER | FEI 编号 |
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED | 报告接收人姓名及职务 |
FIRM NAME | 企业名称 |
STREET ADDRESS | 街道地址 |
CITY, STATE, ZIP CODE, COUNTRY | 城市、州、邮编、国家 |
TYPE ESTABLISHMENT INSPECTED | 被检查企业类型 |
检查官签名 / Signatures
Lisa L. Flores, Investigator
Lisa L. Flores,检查员
Rafeeq A. Habeeb, Investigator
Rafeeq A. Habeeb,检查员
Jared P. Stevens, Investigator
Jared P. Stevens,检查员
观察项 1 / Observation 1
Equipment and utensils are not cleaned or sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.
设备与器具未按适当的时间间隔进行清洁或消毒,以防止可能改变药品安全性、鉴别、含量、质量或纯度的污染。
Specifically,
具体而言,
A. 清洁程序不充分——分配时间不足 / Inadequate Cleaning Procedures – Insufficient Time Allocation
Your firm's written cleaning procedure, SOP CM/PD002 "Cleaning and Sanitization of Production Areas, Other than Production Areas, Wash Areas and Drain Points", establishes requirements for Type A cleaning and Type B cleaning of xxx manufacturing rooms. Type A cleaning is performed during continued production of the same product, while Type B cleaning is performed during product changeover to prevent cross-contamination between different drug products.
贵企业书面清洁程序 SOP CM/PD002《生产区域(生产区域以外的区域、清洗区域及排水点)的清洁与消毒》规定了 xxx 生产房间的 A 类清洁和 B 类清洁要求。A 类清洁在同品种连续生产期间执行,而 B 类清洁在产品更换品种时执行,以防止不同药品之间的交叉污染。
Review of cleaning records for xxx rooms revealed documented cleaning times that are physically insufficient to complete all required procedural steps.
对 xxx 房间清洁记录的审查显示,其记录的清洁时间在客观上不足以完成所有规定的程序步骤。
1. A 类清洁——时间不足的实例 / Type A Cleaning – Examples of Inadequate Times
Type A cleaning requires sequential steps for xxx operations. The following examples demonstrate that documented cleaning times do not allow completion of all required steps:
A 类清洁要求对 xxx 操作按顺序完成若干步骤。以下实例表明,所记录的清洁时间不足以完成所有规定的步骤:
• March 17, 2026: xxx Room xxx (1 minute) – documented as completing xxx
• 2026 年 3 月 17 日:xxx 房间 xxx(1 分钟)——记录为已完成 xxx
• August 18, 2025: xxx Room xxx (5 minutes) – documented as completing xxx
• 2025 年 8 月 18 日:xxx 房间 xxx(5 分钟)——记录为已完成 xxx
• March 18, 2026: xxx Room xxx (5 minutes) – documented as completing xxx
• 2026 年 3 月 18 日:xxx 房间 xxx(5 分钟)——记录为已完成 xxx
2. B 类清洁——时间不足的实例 / Type B Cleaning – Examples of Inadequate Times
Type B cleaning is performed during product changeover and requires more extensive cleaning than Type A, including wet cleaning (using xxx xxx and visual inspection of cleaned areas to confirm effectiveness. Review of Type B cleaning records revealed that documented times are insufficient to complete all required steps:
B 类清洁在产品更换品种期间执行,要求比 A 类清洁更彻底的清洁,包括湿式清洁(使用 xxx xxx)以及对清洁区域进行目视检查以确认清洁效果。对 B 类清洁记录的审查显示,所记录的时间不足以完成所有规定的步骤:
• April 22, 2026: xxx (Unit xxx, Room xxx (14 minutes) – documented as completing wet cleaning of xxx xxx xxx operations, and visual inspection of floor corners, edges, and under-equipment areas
• 2026 年 4 月 22 日:xxx(单元 xxx,房间 xxx)(14 分钟)——记录为已完成 xxx xxx xxx 操作的湿式清洁,并对地面角落、边缘及设备下方区域进行了目视检查
• January 16, 2025: xxx Facility (Unit xxx Room xxx xxx (8 minutes) – documented as completing wet cleaning of xxx xxx
• 2025 年 1 月 16 日:xxx 车间(单元 xxx,房间 xxx xxx)(8 分钟)——记录为已完成 xxx xxx 的湿式清洁
• xxx operations, and required visual inspection.
• xxx 操作及所要求的目视检查。
• February 13, 2025: xxx Facility (Unit xxx Room xxx xxx (5 minutes) – documented as completing wet cleaning of xxx xxx and required visual inspection.
• 2025 年 2 月 13 日:xxx 车间(单元 xxx,房间 xxx xxx)(5 分钟)——记录为已完成 xxx xxx 的湿式清洁及所要求的目视检查。
• February 21, 2025 xxx (Unit xxx Room xxx xxx (11 minutes) – documented as completing wet cleaning of xxx xxx operations, and required visual inspection.
• 2025 年 2 月 21 日:xxx(单元 xxx,房间 xxx xxx)(11 分钟)——记录为已完成 xxx xxx 操作的湿式清洁及所要求的目视检查。
Your firm has not established a minimum or validated cleaning time for Type A and Type B cubicle cleaning. Without scientifically justified time requirements, there is no basis to determine whether documented cleaning times are adequate to complete all required procedural steps.
贵企业未对 A 类和 B 类清洁间清洁建立最低或经验证的清洁时间。在没有科学依据的时间要求的情况下,无法判断所记录的清洁时间是否足以完成所有规定的程序步骤。
B. 缺乏经验证的消毒剂接触时间 / Lack of Validated Contact Time for Disinfectants
1. Protocol MSP/QC/2023/005/00/CMPD002 (effective 13/02/2023) and Summary Report MSR/QC/2023/005/00/CMPD002 (dated 01/06/2024) were conducted to demonstrate the effectiveness of the disinfectants used in the sanitization procedure. However, the study design cannot demonstrate disinfectant efficacy because it lacks the following critical elements:
1. 方案 MSP/QC/2023/005/00/CMPD002(2023 年 2 月 13 日生效)及汇总报告 MSR/QC/2023/005/00/CMPD002(日期 2024 年 6 月 1 日)旨在证明消毒程序中使用的消毒剂的有效性。然而,该研究设计无法证明消毒剂效力,因为其缺少以下关键要素:
• Positive controls
• Pre-cleaning microbial counts
• Deliberate microbial challenge
• Untreated control surfaces
• 阳性对照
• 清洁前微生物计数
• 人为微生物挑战
• 未经处理的对照表面
2. The study's acceptance criteria of "Total aerobic Microbial count: NMT xxx cfu/plate" fails to demonstrate disinfectant efficacy for two reasons:
2. 该研究的接受标准「需氧菌总数:不超过 xxx CFU/皿」无法证明消毒剂效力,原因有二:
• The acceptance criteria is identical to routine environmental monitoring limits for Grade D areas and therefore does not demonstrate disinfectant efficacy. The acceptance criteria measures surface cleanliness, meaning there is no scientific basis to distinguish between effective disinfection and low baseline contamination.
• 该接受标准与 D 级区常规环境监测限度相同,因此不能证明消毒剂效力。该接受标准衡量的是表面洁净度,即没有科学依据可用于区分有效消毒与低基线污染。
• There is no scientific justification for the absence of a log reduction calculation requirement. Your firm's own 2016 validation (Protocol VP/MM/QC/206) established acceptance criteria of ≥xxx %) reduction for vegetative organisms and ≥xxx xxx%) reduction for spores, yet these standards were not applied in Protocol MSP/QC/2023/005/00/CMPD002 (effective 13/02/2023) and Summary Report MSR/QC/2023/005/00/CMPD002 (dated 01/06/2024).
• 未要求计算对数下降缺乏科学依据。贵企业自身的 2016 年验证(方案 VP/MM/QC/206)建立了营养体微生物下降 ≥xxx%)、芽孢下降 ≥xxx xxx%) 的接受标准,但这些标准未应用于方案 MSP/QC/2023/005/00/CMPD002(2023 年 2 月 13 日生效)及汇总报告 MSR/QC/2023/005/00/CMPD002(2024 年 6 月 1 日)。
C. 缺乏经验证的接触时间 / Absence of Validated Contact Time
Your firm has not established or validated a minimum contact time for any of the xxx disinfectants used xxx xxx. The absence of specified contact times, combined with the inadequate total cleaning times documented above, could indicate that effective sanitization is not being achieved. In the documented cleaning records, if all procedural steps are completed within the allocated time, there is no remaining time for disinfectant to remain in contact with floor surfaces before the room is returned to use.
贵企业未对所使用的任何 xxx 消毒剂建立或验证最低接触时间 xxx xxx。缺少规定的接触时间,再加上上述记录的清洁总时间不足,可能表明未能实现有效的消毒。在所记录的清洁记录中,如果在分配的时间内完成所有程序步骤,则在房间恢复使用前,已没有剩余时间让消毒剂与地面保持接触。
观察项 2 / Observation 2
Appropriate controls were not exercised over computer or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel.
未对计算机或相关系统实施适当的控制,以确保主生产与质量控制记录或其他记录的变更仅由经授权的人员实施。
Specifically,
具体而言,
A. xxx 机器 / [redacted] machines
xxx machines—the xxx xxx are all documented as having no electronic data storage or audit trail capability. These machines are used to manufacture multiple tablet products for distribution in the United States, including xxx xxx. As a result:
xxx 机器——xxx xxx 均被记录为不具备电子数据存储或审计追踪能力。这些机器用于生产多个销往美国市场的片剂产品,包括 xxx xxx。因此:
1. The xxx machines lack electronic data storage and audit trail functionality. While printed reports are generated and subsequently scanned for archival, the original electronic data on the machines themselves cannot be retrieved, trended, or audited. This prevents verification of:
1. xxx 机器缺乏电子数据存储和审计追踪功能。虽然打印报告会生成并随后扫描存档,但机器自身的原始电子数据无法检索、无法进行趋势分析、也无法审计。这导致无法核实:
a. Authorization status of changes at the time they were made
b. Detection of unauthorized modifications to data other than process parameters
c. Systematic trending of parameter drift or equipment performance degradation
a. 变更作出时是否处于授权状态
b. 对工艺参数以外的数据进行的未经授权的修改是否能够被识别
c. 参数漂移或设备性能下降的系统性趋势分析
2. There is no documented procedure establishing acceptable limits on the number or magnitude of parameter adjustments an operator may make during a single batch run within the validated range. An operator may make unlimited corrections to xxx or other parameters without documented justification, and there is no mechanism to detect whether such frequent adjustments indicate process instability or equipment drift.
2. 没有成文的程序来规定操作员在验证范围内单批生产运行期间可进行的参数调整次数或幅度的可接受限值。操作员可无限制地修正 xxx 或其他参数而无需书面理由,且没有任何机制可识别此类频繁调整是否表明工艺不稳定或设备漂移。
3. While non-critical alarms are logged in batch records and a Work Request Memo (WRM) system exists to document equipment issues requiring engineering intervention, there is no documented procedure establishing threshold criteria (frequency or severity triggers) that define when non-critical alarms require investigation and escalation beyond routine maintenance.
3. 尽管非关键报警记录在批记录中,且存在用于记录需要工程干预的设备问题的工作请求备忘录(WRM)系统,但没有成文的程序规定阈值标准(频率或严重性触发条件),以明确非关键报警在何种情况下需要超出日常维护范围进行调查和上报。
B. xxx 机器 / [redacted] machines
xxx machines—the xxx—are used to manufacture multiple tablet products for distribution in the United States, including xxx. Although these machines are equipped with electronic data storage and backup capability, appropriate controls are not exercised to assure that changes to process parameters are instituted only by authorized personnel, and procedures do not establish monitoring and investigation requirements for equipment "Non-Critical" alarms and parameter deviations.
xxx 机器——xxx——用于生产多个销往美国市场的片剂产品,包括 xxx。虽然这些机器配备有电子数据存储和备份能力,但未实施适当的控制以确保工艺参数的变更仅由经授权的人员实施,且程序未对设备「非关键」报警和参数偏差建立监测与调查要求。
Specifically:
具体而言:
1. While the electronic audit trail captures date, time, personnel identity, old value, and new value of parameter changes, your procedures do not establish requirements to review the audit trail for: the sequence and frequency of parameter changes during a batch, whether changes were made for documented reasons, whether the pattern of changes indicates process instability or equipment drift, or whether changes were appropriate given the product and process stage. The audit trail is reviewed only for compliance with specification limits, not for assessment of the adequacy or appropriateness of the changes themselves.
1. 虽然电子审计追踪记录了参数变更的日期、时间、人员身份、旧值和新值,但贵企业程序未规定审查审计追踪的要求,以核实:一批生产过程中的参数变更顺序和频率、变更是否具有书面理由、变更模式是否表明工艺不稳定或设备漂移、以及结合产品和工艺阶段判断变更是否适当。审计追踪仅就其是否符合质量标准限度进行审查,而不评估变更本身的充分性或适当性。
2. Your procedures do not establish requirements to monitor the frequency or pattern of non-critical alarms, define investigation criteria or trigger points for repeated non-critical alarms that may indicate emerging equipment problems, or require documentation of non-critical alarm occurrences for trend analysis.
2. 贵企业程序未规定监测非关键报警频率或模式的要求,未定义针对可能表明设备出现新问题的重复非关键报警的调查标准或触发点,也未要求记录非关键报警事件以供趋势分析。
3. While your SOPs establish acceptance limits for process parameters and define alarm thresholds, the procedures do not establish predefined investigation criteria for parameter deviations that do not generate alarms. The SOPs do not establish predefined trigger points for investigation of parameter drift within acceptable limits or trend monitoring of parameters that remain within specification but show directional drift.
3. 虽然贵企业 SOP 规定了工艺参数的接受限值并定义了报警阈值,但程序未对不产生报警的参数偏差建立预先定义的调查标准。SOP 未就可接受限度内的参数漂移调查,或对仍在质量标准范围内但呈现方向性漂移的参数,建立预先定义的触发点。
西门:这倒是可以总结出,报警管理的要求,全部报警事件须记录、监测频率与模式,供趋势分析识别设备劣化;对不触发报警的参数偏差及限度内方向性漂移,也须预设调查触发点,非关键报警须设分级阈值(频率/严重性触发点),超标即启动调查升级,不能止于日常维护;。核心逻辑:监测→分级→调查→趋势闭环,"非关键"不等于可豁免。
观察项 3 / Observation 3
Each component is not tested for conformity with all written specifications for purity, strength, and quality.
并未对每种组分就其纯度、含量和质量的所有书面质量标准进行符合性检验。
Specifically,
具体而言,
Your firm failed to perform individual container testing, including identity testing with limits for xxx (NMT xxx %), on each individual container of each shipment of each lot of high-risk drug components prior to their use in manufacturing of drug products distributed to the United States market. Your procedure for sample testing, Sampling, Testing and Release of Raw Materials, SOP 19/QC006, allows analysis of xxx samples.
贵企业未在用于生产销往美国市场的药品之前,对高风险药品组分的每批(每批来货)的每个独立容器进行逐容器检验,包括规定了限度(不超过 xxx%)的鉴别检验。贵企业样品检验程序《原料的取样、检验与放行》(SOP 19/QC006)允许对 xxx 样品进行分析。
The high-risk raw materials tested using xxx samples include:
采用 xxx 样品进行检验的高风险原料包括:
Raw Material | 原料 |
xxx | xxx |
These raw materials have been used to manufacture commercial product intended for the US market including xxx.
这些原料已用于生产面向美国市场的商业化产品,包括 xxx。
观察项 4 / Observation 4
Control systems for the firm's operations are not adequate to prevent contamination or mix-ups.
企业运营的控制系统不足以防止污染或混淆。
Specifically,
具体而言,
A. 压差监测不足 / Differential Pressure Monitoring
Differential pressure in the manufacturing areas of the xxx facility (Unit xxx) is not adequately monitored and recorded, and no alarm system is in place to detect differential pressure excursions. A review of the Batch Production Record (BPR) for Batch xxx xxx USP xxx mcg), confirmed that the differential pressure is recorded only during active batch production, approximately xxx with no continuous monitoring or alarm system to ensure pressure differentials are maintained. Your firm manufactures xxx drug products approved for the U.S. market in Unit xxx. Approximately xxx distinct batches—including xxx—were shipped to the U.S. between January 2023 and June 2026. Your firm also manufactures xxx tablets in the same facility as xxx products and these xxx tablets are xxx packaged with xxx tablets for at least xxx commercial products marketed in the U.S. All these approximately xxx batches remain within their approved expiry dates as of the date of this inspection (June 30, 2026).
xxx 车间(单元 xxx)生产区域的压差未得到充分监测和记录,且未设置报警系统来识别压差超限。对批次 xxx xxx USP xxx mcg)批生产记录(BPR)的审查确认,压差仅在活跃批次生产期间记录,大约 xxx,没有连续监测或报警系统来确保压差得以维持。贵企业在单元 xxx 生产获准销往美国市场的 xxx 药品。2023 年 1 月至 2026 年 6 月期间,大约 xxx 个不同批次(包括 xxx)已发运至美国。贵企业还在与 xxx 产品相同的车间生产 xxx 片剂,这些 xxx 片剂与 xxx 片剂 xxx 包装,用于至少 xxx 个在美国上市的商业产品。截至本次检查之日(2026 年 6 月 30 日),这些约 xxx 批均未超出其批准的效期。
B. 缺少全面交叉污染风险评估 / No Comprehensive Cross-Contamination Risk Assessment
Although a risk assessment with containment study was done in 2023 and 2025, your firm has not conducted a comprehensive risk assessment prior to this inspection on June 22, 2026, to evaluate the potential for cross-contamination between the xxx manufacturing facility (Unit xxx) and the xxx facility (Unit xxx). The Units are located approximately xxx away from each other. For example, your firm has not performed a scientific evaluation of potential xxx cross-contamination between the two facilities, including an assessment of the location and xxx points of the xxx facility's xxx systems in relation to the xxx vents of the xxx facility; the adequacy and a program for periodic environmental monitoring between the facilities.
尽管在 2023 年和 2025 年进行了含围堵研究的风险评估,但贵企业未在 2026 年 6 月 22 日本次检查之前进行全面风险评估,以评估 xxx 生产车间(单元 xxx)与 xxx 车间(单元 xxx)之间的交叉污染可能性。两个单元相距约 xxx。例如,贵企业未对两个车间之间潜在的 xxx 交叉污染进行科学评估,包括评估 xxx 车间的 xxx 系统的位置和 xxx 点与 xxx 车间 xxx 排风口的关系,以及车间之间定期环境监测的充分性和相关计划。
观察项 5 / Observation 5
Written procedures for annual product reviews are not followed, and the reviews are deficient in that they do not address a review of complaint records for each drug product.
年度产品回顾的书面程序未得到遵循,且回顾存在缺陷,未包含对每种药品投诉记录的回顾。
Specifically,
具体而言,
Your firm failed to include a review of all complaints in the Annual Product Quality Review (APQR). Your procedure, "SOP CM/QA005, Revision 17: Periodic Review of Product Quality of Drug Products," requires the compilation of market complaints for the APQR. However, complaints were not included in the APQR for the following products:
贵企业未将全部投诉的回顾纳入年度产品质量回顾(APQR)。贵企业程序《SOP CM/QA005 第 17 修订版:药品产品质量定期回顾》要求为 APQR 汇编市场投诉。然而,以下产品的投诉未被纳入 APQR:
A. Product: xxx Tablets
A. 产品:xxx 片剂
The APQR for the review period of March 25, 2024, to March 24, 2025 (APQR/25/US/007) reported zero (0) market complaints. However, a review of your firm's complaint records identified eleven (11) complaints associated with this product within the review period that were not included in the APQR including complaints for lack of efficacy and missing blisters.
审查期 2024 年 3 月 25 日至 2025 年 3 月 24 日的 APQR(APQR/25/US/007)报告了零(0)起市场投诉。然而,对贵企业投诉记录的审查发现,审查期内与该产品相关的十一(11)起投诉未纳入该 APQR,包括疗效缺乏和泡罩缺失的投诉。
B. Product: xxx Tablets
B. 产品:xxx 片剂
The APQR for the review period of January 19, 2024, to January 18, 2025 (APQR/25/US/001) reported one (1) market complaint. However, a review of your firm's complaint records identified a total of two (2) complaints associated with this product within the review period. Complaint number MC/I102/2024/0065 for missing blister was not included in the APQR.
审查期 2024 年 1 月 19 日至 2025 年 1 月 18 日的 APQR(APQR/25/US/001)报告了一(1)起市场投诉。然而,对贵企业投诉记录的审查发现,审查期内与该产品相关的投诉共两(2)起。投诉编号 MC/I102/2024/0065(泡罩缺失)未纳入该 APQR。
观察项 6 / Observation 6
Laboratory records do not include complete data derived from all tests, examinations, and assays necessary to assure compliance with established specifications and standards.
实验室记录未包含确保符合既定质量标准与标准所需的所有检验、检查和测定所得数据的完整数据。
Specifically,
具体而言,
Your analysts have been granted user privileges within the Empower software that allow them to view numerical results in the review window—including area counts of peaks—while changing processing methods, without requiring the chromatograms to be saved. This configuration allows for the potential previewing of data. While these series of controls were in place, your firm has tested over xxx batches of finished drug products for assay and/or impurities by HPLC since January 2023. These products include, but are not limited to, xxx.
贵企业分析员被授予了 Empower 软件中的用户权限,使其能够在更改处理方法的同时查看审核窗口中的数值结果(包括峰的峰面积计数),而无须先保存色谱图。该配置造成了数据被预览的可能性。在上述一系列控制措施存在的情况下,自 2023 年 1 月以来,贵企业已通过 HPLC 对超过 xxx 批成品药品进行了含量和/或杂质检验。这些产品包括但不限于 xxx。
Furthermore, prior to this inspection, your firm did not conduct a comprehensive risk assessment to identify and control the data integrity risks introduced by these user privilege configurations.
此外,在本次检查之前,贵企业未进行全面风险评估,以识别和控制这些用户权限配置所引入的数据完整性风险。
西门:今年此类缺陷比较多,empower我自己记录的有以下(可能不全,时间有限没一页一页找)
FDA483:国家级检查员的要求-Empower在Review窗口不得能看到数据预览,一个序列应保证积分方法一致
FDA483:某广东知名生物药企中empower管理缺陷(不是某些公众号说的"漏洞",恰相反是唯一解决方案)
FDA483:生产系统大量孤儿数据(现场被发现遗弃的纸质&电子数据),Empower处理前可以看峰面积,多次向厂家获取灌装线超管
来源:BasicPharma搬砖工 · mp.weixin.qq.com